## Paul J Limburg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11730797/publications.pdf

Version: 2024-02-01

76294 79644 5,591 111 40 73 citations h-index g-index papers 116 116 116 7803 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Accuracy of CT Colonography for Detection of Large Adenomas and Cancers. New England Journal of Medicine, 2008, 359, 1207-1217.	13.9	971
2	Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival. Gastroenterology, 2015, 148, 77-87.e2.	0.6	342
3	Cigarette Smoking and Colorectal Cancer Risk by Molecularly Defined Subtypes. Journal of the National Cancer Institute, 2010, 102, 1012-1022.	3.0	261
4	Young-Onset Colorectal Cancer in Patients With No Known Genetic Predisposition. Medicine (United) Tj ETQq0	0 O rgBT /0	Overlock 10 Tf 170
5	Case–Control Study of Overweight, Obesity, and Colorectal Cancer Risk, Overall and by Tumor Microsatellite Instability Status. Journal of the National Cancer Institute, 2010, 102, 391-400.	3.0	162
6	Efficacy of Antioxidant Supplementation in Reducing Primary Cancer Incidence and Mortality: Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 2008, 83, 23-34.	1.4	155
7	Accuracy of urea breath test in <i>Helicobacter pylori</i> infection: Meta-analysis. World Journal of Gastroenterology, 2015, 21, 1305.	1.4	154
8	Fecal Calprotectin Levels Predict Colorectal Inflammation Among Patients With Chronic Diarrhea Referred for Colonoscopy. American Journal of Gastroenterology, 2000, 95, 2831-2837.	0.2	148
9	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. Journal of the National Cancer Institute, 2014, 106, .	3.0	140
10	Clinically Confirmed Type 2 Diabetes Mellitus and Colorectal Cancer Risk: A Population-Based, Retrospective Cohort Study. American Journal of Gastroenterology, 2006, 101, 1872-1879.	0.2	129
11	Serum Insulin, Glucose, Indices of Insulin Resistance, and Risk of Prostate Cancer. Journal of the National Cancer Institute, 2009, 101, 1272-1279.	3.0	120
12	Prospective Study Reveals Associations Between Colorectal Cancer and Type 2 Diabetes Mellitus or Insulin Use in Men. Gastroenterology, 2010, 139, 1138-1146.	0.6	118
13	Randomized, Placebo-Controlled, Esophageal Squamous Cell Cancer Chemoprevention Trial of Selenomethionine and Celecoxib. Gastroenterology, 2005, 129, 863-873.	0.6	99
14	Tumor Budding in Colorectal Carcinoma. American Journal of Surgical Pathology, 2015, 39, 1340-1346.	2.1	95
15	Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Research and Treatment, 2011, 126, 149-155.	1.1	82
16	Antidiabetic Medications and the Risk of Colorectal Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2258-2268.	1.1	81
17	Insulin, Glucose, Insulin Resistance, and Incident Colorectal Cancer in Male Smokers. Clinical Gastroenterology and Hepatology, 2006, 4, 1514-1521.	2.4	79
18	Association of Aspirin and Nonaspirin Nonsteroidal Anti-inflammatory Drugs With Cancer Incidence and Mortality. Journal of the National Cancer Institute, 2007, 99, 881-889.	3.0	76

#	Article	IF	Citations
19	Effect of Slice Thickness and Primary 2D Versus 3D Virtual Dissection on Colorectal Lesion Detection at CT Colonography in 452 Asymptomatic Adults. American Journal of Roentgenology, 2007, 189, 672-680.	1.0	72
20	Randomized controlled trial of acitretin versus placebo in patients at highâ€risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer, 2012, 118, 2128-2137.	2.0	69
21	Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 622-631.	1.1	68
22	Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ, The, 2016, 355, i6188.	3.0	66
23	Assessing Attitudes Toward Laxative Preparation in Colorectal Cancer Screening and Effects on Future Testing: Potential Receptivity to Computed Tomographic Colonography. Mayo Clinic Proceedings, 2007, 82, 666-671.	1.4	65
24	Prevalence of Alterations in DNA Mismatch Repair Genes in Patients With Young-Onset Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2011, 9, 497-502.	2.4	65
25	Tumor eosinophil infiltration and improved survival of colorectal cancer patients: lowa Women's Health Study. Modern Pathology, 2016, 29, 516-527.	2.9	65
26	Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 133-7.	1.1	65
27	A Useful Technique for Measurement of Back Strength in Osteoporotic and Elderly Patients. Mayo Clinic Proceedings, 1991, 66, 39-44.	1.4	60
28	Nonsteroidal Anti-inflammatory Drugs and Subsite-Specific Colorectal Cancer Incidence in the Iowa Women's Health Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1785-1790.	1.1	60
29	Randomized Phase II Trial of Sulindac, Atorvastatin, and Prebiotic Dietary Fiber for Colorectal Cancer Chemoprevention. Cancer Prevention Research, 2011, 4, 259-269.	0.7	60
30	A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus. Gastroenterology, 2012, 143, 917-926.e1.	0.6	58
31	Prospective Evaluation of Fecal Calprotectin As A Screening Biomarker for Colorectal Neoplasia. American Journal of Gastroenterology, 2003, 98, 2299-2305.	0.2	55
32	Assessing Attitudes Toward Laxative Preparation in Colorectal Cancer Screening and Effects on Future Testing: Potential Receptivity to Computed Tomographic Colonography. Mayo Clinic Proceedings, 2007, 82, 666-671.	1.4	55
33	Body Size and Incident Colorectal Cancer: A Prospective Study of Older Women. Cancer Prevention Research, 2010, 3, 1608-1620.	0.7	51
34	Associations Between Colorectal Cancer Molecular Markers and Pathways With Clinicopathologic Features in Older Women. Gastroenterology, 2013, 145, 348-356.e2.	0.6	49
35	Associations Between Cigarette Smoking Status and Colon Cancer Prognosis Among Participants in North Central Cancer Treatment Group Phase III Trial NO147. Journal of Clinical Oncology, 2013, 31, 2016-2023.	0.8	49
36	Association between Body Mass Index and Mortality for Colorectal Cancer Survivors: Overall and by Tumor Molecular Phenotype. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1229-1238.	1.1	44

#	Article	IF	CITATIONS
37	Cigarette smoking and colorectal cancer: Long-term, subsite-specific risks in a cohort study of postmenopausal women. Clinical Gastroenterology and Hepatology, 2003, 1, 202-210.	2.4	42
38	Metformin Does Not Reduce Markers of Cell Proliferation in Esophageal Tissues of Patients With Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2015, 13, 665-672.e4.	2.4	42
39	Cigarette smoking and colorectal cancer: Long-term, subsite-specific risks in a cohort study of postmenopausal women. Clinical Gastroenterology and Hepatology, 2003, 1, 202-210.	2.4	42
40	Correlation of Trunk Muscle Strength With Age in Children 5 to 18 Years Old. Mayo Clinic Proceedings, 1996, 71, 1047-1054.	1.4	40
41	Genetic Variability in the <i>MTHFR</i> Gene and Colorectal Cancer Risk Using the Colorectal Cancer Family Registry. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 89-100.	1.1	38
42	A Candidate Gene Study of Folate-Associated One Carbon Metabolism Genes and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1812-1821.	1.1	36
43	The National CT Colonography Trial: Assessment of Accuracy in Participants 65 Years of Age and Older. Radiology, 2012, 263, 401-408.	3.6	36
44	Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut, 2012, 61, 1299-1305.	6.1	36
45	Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guidelines. Journal of Oncology Practice, 2015, 11, e437-e441.	2.5	35
46	Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. Cancer Prevention Research, 2017, 10, 345-354.	0.7	35
47	Associations Between Intake of Folate and Related Micronutrients with Molecularly Defined Colorectal Cancer Risks in the Iowa Women's Health Study. Nutrition and Cancer, 2012, 64, 899-910.	0.9	33
48	Cigarette Smoking and Colorectal Cancer Risk by KRAS Mutation Status Among Older Women. American Journal of Gastroenterology, 2012, 107, 782-789.	0.2	32
49	Helicobacter pylori seropositivity and colorectal cancer risk: a prospective study of male smokers. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 1095-9.	1.1	32
50	Aspirin Prevents Colorectal Cancer by Normalizing EGFR Expression. EBioMedicine, 2015, 2, 447-455.	2.7	31
51	Gene Expression Differences in Normal Esophageal Mucosa Associated with Regression and Progression of Mild and Moderate Squamous Dysplasia in a High-Risk Chinese Population. Cancer Research, 2006, 66, 6851-6860.	0.4	27
52	National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences. Cancer Prevention Research, 2021, 14, 603-614.	0.7	27
53	Genes involved with folate uptake and distribution and their association with colorectal cancer risk. Cancer Causes and Control, 2010, 21, 597-608.	0.8	26
54	Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45–49 Year-Olds: A Cross-Sectional Study. Cancer Prevention Research, 2021, 14, 489-496.	0.7	26

#	Article	IF	Citations
55	Postmenopausal Hormone Therapy and Colorectal Cancer Risk in Relation to Somatic <i>KRAS</i> Mutation Status among Older Women. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 681-684.	1.1	25
56	Noncathartic CT Colonography: Image Quality Assessment and Performance and in a Screening Cohort. American Journal of Roentgenology, 2013, 201, 787-794.	1.0	24
57	Circulating Prostaglandin Biosynthesis in Colorectal Cancer and Potential Clinical Significance. EBioMedicine, 2015, 2, 165-171.	2.7	24
58	Doubleâ€blind, randomized phase 3 trial of lowâ€dose 13â€cis retinoic acid in the prevention of second primaries in head and neck cancer: Longâ€term followâ€up of a trial of the Eastern Cooperative Oncology Groupâ€ACRIN Cancer Research Group (C0590). Cancer, 2017, 123, 4653-4662.	2.0	24
59	Marine omegaâ€3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial NO147 (Alliance). International Journal of Cancer, 2019, 145, 380-389.	2.3	22
60	Bisphosphonates Are Associated With Reduced Risk of Colorectal Cancer: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2013, 11, 232-239.e1.	2.4	21
61	Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. Mayo Clinic Proceedings, 2016, 91, 71-80.	1.4	20
62	Use of Folic Acid–Containing Supplements after a Diagnosis of Colorectal Cancer in the Colon Cancer Family Registry. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2023-2034.	1.1	18
63	Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model. PLoS ONE, 2020, 15, e0244431.	1.1	18
64	Alcohol Intake and Colorectal Cancer Risk by Molecularly Defined Subtypes in a Prospective Study of Older Women. Cancer Prevention Research, 2011, 4, 2035-2043.	0.7	17
65	Population Pharmacokinetic Model for Cancer Chemoprevention With Sulindac in Healthy Subjects. Journal of Clinical Pharmacology, 2013, 53, 403-412.	1.0	17
66	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial NO147. International Journal of Cancer, 2016, 139, 986-995.	2.3	16
67	Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia. Cancer Prevention Research, 2021, 14, 573-580.	0.7	16
68	A high-throughput 3-parameter flow cytometry-based cell death assay. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2007, 71A, 170-173.	1.1	14
69	IGF-I, IGFBP-3, and IGF-I/IGFBP-3 Ratio: No Association with Incident Colorectal Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1832-1834.	1.1	14
70	Immunodiscrimination of colorectal neoplasia using MUC1 antibodies: discrepant findings in tissue versus stool. Digestive Diseases and Sciences, 2000, 45, 494-499.	1.1	13
71	Comparative Bioavailability of Sulindac in Capsule and Tablet Formulations. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 674-679.	1.1	13
72	Common variants in the obesity-associated genes FTO and MC4R are not associated with risk of colorectal cancer. Cancer Epidemiology, 2016, 44, 1-4.	0.8	12

#	Article	IF	CITATIONS
73	Barriers to utilization of three colorectal cancer screening options – Data from a national survey. Preventive Medicine Reports, 2021, 24, 101508.	0.8	12
74	Associations between Cigarette Smoking, Hormone Therapy, and Folate Intake with Incident Colorectal Cancer by TP53 Protein Expression Level in a Population-Based Cohort of Older Women. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 350-355.	1.1	11
75	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG NO147 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 696-703.	1.1	11
76	Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a large, nationally insured cohort. International Journal of Colorectal Disease, 2021, 36, 2471-2480.	1.0	11
77	Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 713-719.	1.1	10
78	Colorectal cancer screening completion: An examination of differences by screening modality. Preventive Medicine Reports, 2020, 20, 101202.	0.8	9
79	Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development. EBioMedicine, 2019, 49, 145-156.	2.7	8
80	Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes. Cancer Prevention Research, 2021, 14, 845-850.	0.7	8
81	CT Colonography for the Detection of Nonpolypoid Adenomas: Sensitivity Assessed With Restricted National CT Colonography Trial Criteria. American Journal of Roentgenology, 2014, 203, W614-W622.	1.0	7
82	Recent trends in colorectal cancer screening methods based on Medicare claims data. Current Medical Research and Opinion, 2021, 37, 605-607.	0.9	7
83	Multitarget Stool DNA for Average Risk Colorectal Cancer Screening. Gastrointestinal Endoscopy Clinics of North America, 2020, 30, 553-568.	0.6	7
84	Provider-perceived barriers to patient adherence to colorectal cancer screening. Preventive Medicine Reports, 2022, 25, 101681.	0.8	7
85	Well-Being Champion Impact on Employee Engagement, Staff Satisfaction, and EmployeeÂWell-Being. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 106-115.	1.2	6
86	Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biology and Therapy, 2021, 22, 544-553.	1.5	6
87	Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use. Mayo Clinic Proceedings, 2022, 97, 101-109.	1.4	6
88	Serum Cytokine Analysis in a Positive Chemoprevention Trial: Selenium, Interleukin-2, and an Association with Squamous Preneoplastic Disease. Cancer Prevention Research, 2010, 3, 810-817.	0.7	5
89	Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model. Current Medical Research and Opinion, 2021, 37, 1005-1010.	0.9	5
90	An examination of socioeconomic and racial/ethnic disparities in the awareness, knowledge and utilization of three colorectal cancer screening modalities. SSM - Population Health, 2021, 14, 100780.	1.3	5

#	Article	IF	Citations
91	Colorectal cancer chemoprevention. Chinese Journal of Digestive Diseases, 2004, 5, 7-11.	1.1	4
92	Selenomethionine Treatment Does Not Alter Gene Expression in Normal Squamous Esophageal Mucosa in a High-Risk Chinese Population. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1046-1047.	1.1	4
93	Socioeconomic Inequalities in the Utilization of Colorectal Stents for the Treatment of Malignant Bowel Obstruction. Digestive Diseases and Sciences, 2016, 61, 1669-1676.	1.1	4
94	Comparison of Tissue-Based Molecular Markers in Younger versus Older Patients with Colorectal Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1570-1576.	1.1	4
95	Impact of screening and followâ€up colonoscopy adenoma sensitivity on colorectal cancer screening outcomes in the CRCâ€AIM microsimulation model. Cancer Medicine, 2021, 10, 2855-2864.	1.3	4
96	Factors Associated With Clinician Recommendations for Colorectal Cancer Screening Among Average-Risk Patients: Data From a National Survey. Preventing Chronic Disease, 2022, 19, E19.	1.7	4
97	Healthcare Provider Perspectives on Lowering Colorectal Cancer Screening Initiation Age to 45 Years: Results From a Survey of Clinicians in the U.S Cancer Control, 2020, 27, 107327482097711.	0.7	3
98	Reply. Clinical Gastroenterology and Hepatology, 2013, 11, 1209-1210.	2.4	2
99	Patient preferences on general health and colorectal cancer screening decision-making: Results from a national survey. Patient Education and Counseling, 2021, , .	1.0	2
100	Life-years gained resulting from screening colonoscopy compared with follow-up colonoscopy after a positive stool-based colorectal screening test. Preventive Medicine Reports, 2022, 26, 101701.	0.8	2
101	CYTOTOXIC PROPERTIES OF DIOSPYROS SEYCHELLARUM EXTRACT. Journal of Toxicological Sciences, 2007, 32, 487-493.	0.7	1
102	Gastrointestinal Neoplasia: Current Perspectives and Emerging Frontiers. Gastroenterology Clinics of North America, 2016, 45, xi-xii.	1.0	1
103	A Randomized Controlled Trial in the Evaluation of a Novel Stress Management Tool: A Lounge Chair Experience. Global Advances in Health and Medicine, 2019, 8, 216495611989259.	0.7	1
104	Associations between tissueâ€based CD3+ Tâ€lymphocyte count and colorectal cancer survival in a prospective cohort of older women. Molecular Carcinogenesis, 2021, 60, 15-24.	1.3	1
105	Initial validation of a self-report questionnaire based on the Theoretical Domains Framework: determinants of clinician adoption of a novel colorectal cancer screening strategy. Implementation Science Communications, 2021, 2, 119.	0.8	1
106	Impact of the Sessile Serrated Polyp Pathway on Predicted Colorectal Cancer Outcomes., 2022, 1, 55-62.		1
107	Colorectal cancer screening education: Developing a competency-based curriculum for medical training programs. Journal of Cancer Education, 2007, 22, 206-207.	0.6	0
108	Glycemic response of type 2 diabetics to sweetened dried cranberries. FASEB Journal, 2009, 23, 900.6.	0.2	0

#	Article	IF	CITATIONS
109	A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147 Journal of Clinical Oncology, 2012, 30, 446-446.	0.8	O
110	Multicancer early detection: International summit to Clarify the Roadmap. Cancer, 2022, 128, 859-860.	2.0	0
111	Chemoprevention of colorectal cancer: aspirin and beyond. Clinical Advances in Hematology and Oncology, 2018, 16, 552-554.	0.3	O